Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'

被引：3
|
作者：
Imafuku, Keisuke [1 ,2 ]
Yoshino, Koji [1 ]
Yamaguchi, Kei [1 ]
Tsuboi, Satoshi [1 ]
Ohara, Kuniaki [1 ]
Hata, Hiroo [2 ]
机构：
[1] Komagome Hosp, Dept Dermatol, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo 1138677, Japan
[2] Hokkaido Univ, Dept Dermatol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan
来源：
BRITISH JOURNAL OF CANCER | 2017年 / 116卷 / 08期
关键词：
NIVOLUMAB;
D O I：
10.1038/bjc.2017.58
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e14 / e14
页数：2
相关论文
共 50 条
  • [1] Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’
    Keisuke Imafuku
    Koji Yoshino
    Kei Yamaguchi
    Satoshi Tsuboi
    Kuniaki Ohara
    Hiroo Hata
    [J]. British Journal of Cancer, 2017, 116 : e14 - e14
  • [2] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    Bowyer, S.
    Prithviraj, P.
    Lorigan, P.
    Larkin, J.
    McArthur, G.
    Atkinson, V.
    Millward, M.
    Khou, M.
    Diem, S.
    Ramanujam, S.
    Kong, B.
    Liniker, E.
    Guminski, A.
    Parente, P.
    Andrews, M. C.
    Parakh, S.
    Cebon, J.
    Long, G. V.
    Carlino, M. S.
    Klein, O.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
  • [3] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
    S Bowyer
    P Prithviraj
    P Lorigan
    J Larkin
    G McArthur
    V Atkinson
    M Millward
    M Khou
    S Diem
    S Ramanujam
    B Kong
    E Liniker
    A Guminski
    P Parente
    M C Andrews
    S Parakh
    J Cebon
    G V Long
    M S Carlino
    O Klein
    [J]. British Journal of Cancer, 2016, 114 : 1084 - 1089
  • [4] Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
    Bowyer, Samantha
    Prithviraj, Prashanth
    Lorigan, Paul
    Larkin, James
    McArthur, Grant
    Atkinson, Victoria
    Millward, Michael
    Khou, Muoi
    Diem, Stefan
    Ramanujam, Sangeetha
    Kong, Ben
    Liniker, Elizabeth
    Guminski, Alexander
    Parente, Phillip
    Andrews, Miles C.
    Parakh, Sagun
    Cebon, Jonathan
    Long, Georgina V.
    Carlino, Matteo S.
    Klein, Oliver
    [J]. BRITISH JOURNAL OF CANCER, 2017, 116 (08) : e15 - e15
  • [5] Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy’’
    Samantha Bowyer
    Prashanth Prithviraj
    Paul Lorigan
    James Larkin
    Grant McArthur
    Victoria Atkinson
    Michael Millward
    Muoi Khou
    Stefan Diem
    Sangeetha Ramanujam
    Ben Kong
    Elizabeth Liniker
    Alexander Guminski
    Phillip Parente
    Miles C Andrews
    Sagun Parakh
    Jonathan Cebon
    Georgina V Long
    Matteo S Carlino
    Oliver Klein
    [J]. British Journal of Cancer, 2017, 116 : e15 - e15
  • [6] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy
    Prithviraj, Prashanth
    McArthur, Grant A.
    Atkinson, Victoria
    Parente, Phillip
    Andrews, Miles Cameron
    Parakh, Sagun
    Cebon, Jonathan S.
    Klein, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [8] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    [J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [9] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [10] Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
    Savoia, Paola
    Astrua, Chiara
    Fava, Paolo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1092 - 1101
12345